RS64179B1 - Dual targeting - Google Patents

Dual targeting

Info

Publication number
RS64179B1
RS64179B1 RS20230337A RSP20230337A RS64179B1 RS 64179 B1 RS64179 B1 RS 64179B1 RS 20230337 A RS20230337 A RS 20230337A RS P20230337 A RSP20230337 A RS P20230337A RS 64179 B1 RS64179 B1 RS 64179B1
Authority
RS
Serbia
Prior art keywords
dual targeting
targeting
dual
Prior art date
Application number
RS20230337A
Other languages
Serbian (sr)
Inventor
Roland Beckmann
Hobolt Kristian Jensen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of RS64179B1 publication Critical patent/RS64179B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1228Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K16/1232Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia from Escherichia (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243Colony Stimulating Factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/248IL-6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1058Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Ecology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RS20230337A 2011-05-27 2012-05-29 Dual targeting RS64179B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11004373 2011-05-27
PCT/EP2012/002279 WO2012163520A1 (en) 2011-05-27 2012-05-29 Dual targeting
EP12725311.0A EP2726510B1 (en) 2011-05-27 2012-05-29 Dual targeting

Publications (1)

Publication Number Publication Date
RS64179B1 true RS64179B1 (en) 2023-05-31

Family

ID=46207961

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20230337A RS64179B1 (en) 2011-05-27 2012-05-29 Dual targeting

Country Status (19)

Country Link
US (4) US20140206846A1 (en)
EP (1) EP2726510B1 (en)
JP (2) JP2014516542A (en)
CN (2) CN112661848A (en)
AU (1) AU2012265156B2 (en)
CA (1) CA2853383C (en)
DK (1) DK2726510T3 (en)
ES (1) ES2943577T3 (en)
FI (1) FI2726510T3 (en)
HR (1) HRP20230411T1 (en)
HU (1) HUE061692T2 (en)
IL (1) IL229649B (en)
LT (1) LT2726510T (en)
PL (1) PL2726510T3 (en)
PT (1) PT2726510T (en)
RS (1) RS64179B1 (en)
SG (2) SG10201604279TA (en)
SI (1) SI2726510T1 (en)
WO (1) WO2012163520A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2891566A1 (en) 2012-12-05 2014-06-12 Dutalys Gmbh Dual targeting
MX2016006529A (en) * 2013-12-20 2016-08-03 Genentech Inc Dual specific antibodies.
BR112016030740A2 (en) 2014-07-01 2018-02-20 Pfizer Inc. bispecific heterodimeric bodies and their uses
MX2017004076A (en) 2014-09-29 2017-07-04 Univ Duke Bispecific molecules comprising an hiv-1 envelope targeting arm.
WO2016149695A1 (en) 2015-03-19 2016-09-22 Duke University HIV-1 NEUTRALIZING ANTIBODIES AND USES THEREOF (CD4bs ANTIBODIES)
US11071783B2 (en) 2015-03-19 2021-07-27 Duke University HIV-1 neutralizing antibodies and uses thereof
EP3271022A4 (en) 2015-03-19 2018-10-31 Duke University Hiv-1 neutralizing antibodies and uses thereof
WO2016149698A2 (en) 2015-03-19 2016-09-22 Duke University Hiv-1 neutralizing antibodies and uses thereof (v3 antibodies)
CN109791149A (en) 2016-09-30 2019-05-21 豪夫迈·罗氏有限公司 The dual combination measuring method based on SPR for functional analysis multispecific molecule
EP3330289A1 (en) 2016-12-02 2018-06-06 Friedrich-Alexander-Universität Erlangen-Nürnberg A cd33-, cd16- and cd123-specific single chain triplebody
GB201711208D0 (en) 2017-07-12 2017-08-23 Iontas Ltd Ion channel inhibitors
US20190270806A1 (en) * 2018-03-02 2019-09-05 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CA3123503A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Antibody that binds to vegf and il-1beta and methods of use
JP7241888B2 (en) 2018-12-30 2023-03-17 エフ. ホフマン-ラ ロシュ アーゲー Binding assay based on pH gradient SPR
WO2020200941A1 (en) 2019-03-29 2020-10-08 F. Hoffmann-La Roche Ag Spr-based binding assay for the functional analysis of multivalent molecules
WO2020200944A1 (en) 2019-03-29 2020-10-08 F. Hoffmann-La Roche Ag Method for generating avid-binding multispecific antibodies
WO2020254355A1 (en) 2019-06-19 2020-12-24 F. Hoffmann-La Roche Ag Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
BR112021025401A2 (en) 2019-06-19 2022-02-01 Hoffmann La Roche Methods for producing a trivalent antibody, deoxyribonucleic acid, use of a deoxyribonucleic acid, recombinant mammalian cell, composition and method for producing a recombinant mammalian cell
CA3140192A1 (en) 2019-06-19 2020-12-24 Johannes Auer Method for the generation of a multivalent, multispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
EP3986927A1 (en) 2019-06-19 2022-04-27 F. Hoffmann-La Roche AG Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
AU2020294880B2 (en) 2019-06-19 2024-05-02 F. Hoffmann-La Roche Ag Method for the generation of a protein expressing cell by targeted integration using Cre mRNA
CN114026224B (en) 2019-06-26 2024-03-15 豪夫迈·罗氏有限公司 Mammalian cell lines with SIRT-1 gene knockouts
AU2020364071A1 (en) 2019-10-10 2022-05-26 Kodiak Sciences Inc. Methods of treating an eye disorder
WO2021084104A1 (en) 2019-10-30 2021-05-06 Bioinvent International Ab Tetravalent antibody molecules
CN114902052A (en) 2020-01-02 2022-08-12 豪夫迈·罗氏有限公司 ADA response specificity assay
WO2021198034A1 (en) 2020-03-30 2021-10-07 F. Hoffmann-La Roche Ag Antibody that binds to vegf and pdgf-b and methods of use
JP7158626B1 (en) 2020-09-04 2022-10-21 エフ.ホフマン-ラ ロシュ アーゲー Antibodies that bind to VEGF-A and ANG2 and methods of use
CN116391037A (en) 2020-09-24 2023-07-04 豪夫迈·罗氏有限公司 Mammalian cell lines with gene knockout
CN116670282A (en) 2020-12-22 2023-08-29 豪夫迈·罗氏有限公司 XBP 1-targeting oligonucleotides
EP4295154A1 (en) 2021-02-18 2023-12-27 F. Hoffmann-La Roche AG Method for resolving complex, multistep antibody interactions
EP4320444A1 (en) 2021-04-09 2024-02-14 F. Hoffmann-La Roche AG Process for selecting cell clones expressing a heterologous polypeptide
WO2023117325A1 (en) 2021-12-21 2023-06-29 F. Hoffmann-La Roche Ag Method for the determination of hydrolytic activity
WO2023202967A1 (en) 2022-04-19 2023-10-26 F. Hoffmann-La Roche Ag Improved production cells
WO2023217933A1 (en) 2022-05-11 2023-11-16 F. Hoffmann-La Roche Ag Antibody that binds to vegf-a and il6 and methods of use
WO2023232961A1 (en) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Improved production cells
WO2024079069A1 (en) 2022-10-12 2024-04-18 F. Hoffmann-La Roche Ag Method for classifying cells

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ATE219517T1 (en) 1995-08-18 2002-07-15 Morphosys Ag PROTEIN/(POLY)PEPTIDE LIBRARIES
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
CN1451043A (en) 2000-06-29 2003-10-22 艾博特公司 Dual specificity antibodies and methods of making and using
ATE477280T1 (en) * 2001-06-28 2010-08-15 Domantis Ltd DOUBLE-SPECIFIC LIGAND AND USE THEREOF
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US7749724B2 (en) 2005-07-05 2010-07-06 Washington State University Fluorogenic selective and differential medium for isolation of Enterobacter sakazakii
WO2007112940A2 (en) 2006-03-31 2007-10-11 Ablynx N.V. Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same
WO2008027236A2 (en) * 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies

Also Published As

Publication number Publication date
IL229649A0 (en) 2014-01-30
AU2012265156B2 (en) 2017-01-19
HRP20230411T1 (en) 2023-07-07
JP2014516542A (en) 2014-07-17
EP2726510B1 (en) 2023-03-08
HUE061692T2 (en) 2023-08-28
NZ619409A (en) 2016-05-27
IL229649B (en) 2019-08-29
US20180094078A1 (en) 2018-04-05
AU2012265156A1 (en) 2014-01-16
CN103930445B (en) 2021-03-09
DK2726510T3 (en) 2023-05-15
JP2017221200A (en) 2017-12-21
JP6659626B2 (en) 2020-03-04
CN103930445A (en) 2014-07-16
PT2726510T (en) 2023-05-03
PL2726510T3 (en) 2023-05-29
US20140206846A1 (en) 2014-07-24
SG195196A1 (en) 2013-12-30
US20210079119A1 (en) 2021-03-18
SI2726510T1 (en) 2023-06-30
FI2726510T3 (en) 2023-05-04
CA2853383A1 (en) 2012-12-06
WO2012163520A1 (en) 2012-12-06
SG10201604279TA (en) 2016-07-28
US20230279155A1 (en) 2023-09-07
CA2853383C (en) 2021-04-06
LT2726510T (en) 2023-05-10
CN112661848A (en) 2021-04-16
EP2726510A1 (en) 2014-05-07
ES2943577T3 (en) 2023-06-14
WO2012163520A4 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
IL229649A0 (en) Dual targeting
IL236563A0 (en) Search-powered connection targeting
DK3798230T3 (en) Terapeutiske antistoffer
EP2715659A4 (en) Überfeed
EP2754063A4 (en) Smb2 scaleout
EP2723631A4 (en) Quadfolier
PL3219801T3 (en) Construct
AP2014007621A0 (en) 2-Thiopyrimidinones
EP2695208A4 (en) Micro-thermocouple
ZA201304139B (en) Combination
PL2606715T3 (en) Baler-wrapper combination
EP2679138A4 (en) Endsoscope
EP2708561A4 (en) Bio-pin
DK2770906T3 (en) Applanationstonometer
EP2698098A4 (en) Campimeter
EP2694655A4 (en) pAVEC
HK1211953A1 (en) Dual targeting
EP2702929A4 (en) Campimeter
EP2672969A4 (en) Combination
AU4540P (en) BUNNAN Baloskion tetraphyllum
AU5171P (en) Sunparamiho Mandevilla xamabilis
AU5031P (en) BESYS Beschorneria yuccoides
AU5026P (en) Goldstrike Agapanthus inapertus
IL213949A0 (en) Aerial targeting
AP00723S1 (en) Autorickshaw